Skip to content

Observation on the efficacy of temporary spinal cord stimulation with different electrical pulse densities for herpes zoster-associated

Observation on the efficacy of temporary spinal cord stimulation with different electrical pulse densities for herpes zoster-associated

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118616
Enrollment
Unknown
Registered
2026-02-09
Start date
2022-04-22
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Herpes zoster

Interventions

Traditional pulse density group:pulse density 0.4%–2.1%,calculated as frequency×pulse width
High pulse density group:pulse density 0.4%–2.1%,with distinct coordinated programming parameters

Sponsors

The Second Affiliated Hospital of Guangxi Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age >= 50 years old, American Society of Anesthesiologists (ASA) classification level I-II; (2) Meets the diagnostic criteria for herpes zoster-related pain (ZAP); (3) Unilateral herpes zoster in the cervical/thoracic nerve dermatome distribution area; (4) Pain control is not satisfactory after 1 week of comprehensive treatment (including medication and nerve block) (Numeric Pain Score >= 4 points) or the patient cannot tolerate the adverse reactions of the medication, and the patient has not received radiofrequency treatment before; (5) Spinal cord electrical stimulation (SCS) test electrodes are implanted in the posterior column of the spinal cord; (6) Received short-term spinal cord electrical stimulation (SCS) treatment (course of 11 days).

Exclusion criteria

Exclusion criteria: (1) Severe heart, liver, kidney or other major organ dysfunction; (2) Hypertension, diabetes, autoimmune diseases or malignant tumors; (3) Spinal deformity or local infection at puncture site; (4) Abnormal bleeding/coagulation; (5) Mental/intellectual disorders or communication difficulties.

Design outcomes

Primary

MeasureTime frame
Pain characteristics;

Secondary

MeasureTime frame
Sleep Quality;Quality of life;Therapeutic Effect;Levels of Inflammatory Markers;

Countries

China

Contacts

Public ContactQin Yansheng

The Second Affiliated Hospital of Guangxi Medical University

202300265@sr.gxmu.edu.cn+86 771 337 0716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026